Market Cap: $97.53B
Market Cap: $97.53B

GSK plc ( GSK ) stands at a crucial juncture as it navigates the complex landscape of biopharmaceuticals, aiming to secure and enhance its market position amidst impending patent expirations and an ev…

GSK Plc (Ticker: GSK) makes significant strides in addressing unmet medical needs for patients with pyelonephritis, a challenging kidney infection. The focus on innovative treatment pathways underscor…

On June 10, 2026, GSK Plc (Ticker: GSK) announces its strategic acquisition of Nuvalent, Inc., a clinical-stage precision oncology firm, for $10.6 billion. This acquisition exemplifies GSK's commitmen…
U.S. Government’s Vaccine Advisory Panel Actions Under Legal Scrutiny A federal court's recent commentary on the U.S. government's handling of vaccine recommendations signals a significant development…
GSK Expands Prescription Offerings, Enhancing Accessibility for Consumers GSK Plc makes significant strides in expanding its portfolio of discounted prescription medications, increasing the total numb…
GSK Expands Prescription Offerings to Enhance Accessibility and Affordability GSK Plc is poised to make significant advancements in the realm of affordable healthcare with its recent decision to expan…
### GSK’s Pioneering Step in Pediatric Respiratory Care On Friday, GSK plc achieves a major milestone in respiratory health when the U.S. Food and Drug Administration (FDA) expands the approved age in…
GSK’s Expanded Efforts Against RSV: A Significant Regulatory Milestone The recent approval by the U.S. Food and Drug Administration (FDA) to expand the age indication for GSK plc's respiratory syncyti…
GSK Settles Class Action Over BOOSTRIX Marketing Practices GSK Plc has recently reached a settlement in a class action lawsuit that revolves around allegations concerning the misleading advertising of…
Settlement Announcement Marks New Chapter for GSK Plc Amid BOOSTRIX Controversy GSK Plc finds itself navigating a significant legal development as the company agrees to a class action settlement regar…
GSK’s Anticipated Growth Amid Market Fluctuations GSK Plc, a leading player in the global pharmaceuticals industry, focuses heavily on research and development, aiming to bring innovative therapies to…
GSK's Strategic Focus on Long-Term Growth Initiatives GSK Plc is actively advancing its strategy in the biopharmaceutical sector, positioning itself to fortify its long-term growth trajectory. The com…
GSK Plc's Strategic Focus on Long-term Growth Potential in Pharma Innovations GSK Plc continues to concentrate its efforts on delivering innovative pharmaceutical solutions, catering to unmet medical…
GSK's Strategic Move to Enhance Therapeutic Pipeline through Licensing Agreement with Frontier Biotechnologies In a pivotal step towards expanding its biopharmaceutical capabilities, GSK Plc signs an…
GSK Advances siRNA Drug Development Through Partnership with Frontier Biotechnologies GSK Plc solidifies its commitment to innovative biopharmaceutical solutions through a newly announced exclusive li…
Frontier Biotech and GSK Forge Strategic Alliance in siRNA Therapeutics Frontier Biotechnologies Inc. recently announces an exclusive licensing agreement with GSK, establishing a notable partnership i…
GSK’s communications face a recurring problem when source excerpts omit the company name Communications teams at GSK and across the pharmaceutical sector regularly confront a practical obstacle: summa…
GSK and JAX‑NYSCF set five‑year plan to humanise neurodegeneration research GSK Plc is entering a five‑year strategic research collaboration with the Jackson Laboratory–New York Stem Cell Foundation C…
GSK and JAX‑NYSCF form five‑year alliance to model Alzheimer’s in human cells Building scalable, patient-derived cellular platforms to speed translation GSK announces a strategic, five‑year research c…
AI for Law Firms Forces a Re‑Think in Pharma Compliance and M&A for GSK Anthropic’s new program for smaller law firms prompts a rapid reassessment across industries, and pharmaceutical groups such as…
GSK Confronts AI-driven Shake-up in Pharma Legal and Funding Landscape AI's immediate pressure on lawyers, funders and drug development Pharmaceutical giant GSK faces a near-term industry shake-up as…
Securing Minerals, Protecting Medicines: What the U.S. Conference Means for GSK The U.S. State Department is hosting miners from 50 countries this week as Washington and Brussels push to strengthen st…
GSK and Helix Forge Strategic Alliance to Advance Genomic Research In a significant development for GSK Plc, the global biopharmaceutical company announces a multi-year strategic collaboration with He…
Strategic Collaboration Positions GSK at the Forefront of Genomic Research In a significant development within the biopharmaceutical sector, GSK Plc has entered into a multi-year strategic collaborati…
GSK's Strategic Leap into Genomic Research with Helix Collaboration GSK Plc is making significant strides in its research and development efforts by entering into a multi-year strategic collaboration…
GSK Faces Pricing Pressure Amid Industry-Wide Drug Hikes In a significant development for the pharmaceutical sector, drugmakers, including GSK Plc, are poised to implement price increases on over 350…
GSK Faces Price Hike Challenges in a Competitive Pharmaceutical Landscape In a significant development within the pharmaceutical sector, GSK Plc and other major drug manufacturers are poised to increa…
Price Increases in Pharmaceutical Industry: A Double-Edged Sword for Patients and Innovation Recent announcements reveal that drug manufacturers, including GSK Plc, plan to raise prices on more than 3…
Samsung Biologics Enhances U.S. Manufacturing Capabilities with GSK Acquisition Samsung Biologics, a leading contract development and manufacturing organization (CDMO), makes a significant move to bol…
GSK's Role in Evolving Pharmaceutical Pricing Landscape In a significant policy shift, the U.S. government, led by President Donald Trump, announces agreements with major pharmaceutical companies to r…
GSK Partners with CAMP4 Therapeutics to Advance RNA-targeted Therapies GlaxoSmithKline Plc (GSK) enters into a strategic research collaboration with CAMP4 Therapeutics Corporation, focusing on RNA-tar…
GSK and CAMP4 Therapeutics Forge Strategic Alliance for RNA Therapies In a significant move to enhance its research capabilities, GSK Plc (NYSE:GSK) has entered a strategic collaboration with CAMP4 Th…
GSK’s Breakthrough in Gonorrhoea Treatment: FDA Approves Gepotidacin GSK Plc achieves a significant milestone as the U.S. Food and Drug Administration (FDA) approves its supplemental New Drug Applicat…
GSK's Breakthrough in Gonorrhoea Treatment: A New Hope Against Resistance In a pivotal move for public health, GSK Plc announces that the U.S. Food and Drug Administration (FDA) has granted approval f…
GSK's Short Interest Decline Signals Changing Investor Sentiment GSK Plc, a leading player in the pharmaceutical industry, sees a significant reduction in its short interest, which has dropped by 12.6…
GSK's Short Interest Decline Suggests Market Confidence in Recovery GSK Plc, a prominent player in the pharmaceutical industry, recently reports a significant decrease in its short interest, dropping…
Revolutionizing Drug Pricing: U.K. Government's Initiative with Pharmaceutical Executives The U.K. government is currently engaging senior executives from leading pharmaceutical companies to redefine…
Strengthening Trade Ties: A New Era for British Pharmaceuticals The recent agreement between the U.K. and the U.S. to eliminate tariffs on British pharmaceutical exports marks a transformative develop…
Strengthening Transatlantic Trade: A New Era for British Pharmaceuticals In a landmark agreement, the UK and the U.S. eliminate tariffs on British pharmaceutical products exported to America, heraldin…
GSK Faces New Price Negotiation Landscape Amid U.S. Drug Pricing Reforms GSK Plc is navigating a transformative period in the pharmaceutical industry as new U.S. drug pricing regulations take center s…
GSK Faces New Pricing Landscape Under Medicare Negotiations In a significant development for the pharmaceutical industry, GSK Plc finds itself at the forefront of the changing drug pricing landscape a…
GSK Faces Major Pricing Adjustments Amid New Medicare Negotiations The pharmaceutical industry is undergoing a transformative phase as the U.S. government implements new pricing regulations that signi…
GSK Subsidiary Takes Legal Action Over Patent Dispute in Biotech Sector GSK plc's subsidiary, Tesaro Inc., initiates a legal battle against AnaptysBio, Inc. in the Delaware Chancery Court, marking a s…
GSK and Flagship Pioneering Forge New Frontiers in Disease Treatment GSK Plc strengthens its commitment to addressing unmet medical needs through a strategic collaboration with Flagship Pioneering. Th…
GSK and Ochre Bio Forge Groundbreaking Collaboration in RNA Therapeutics for Liver Diseases GSK Plc solidifies its commitment to innovative healthcare solutions through a pivotal collaboration with bi…
GSK and Ochre Bio Forge Groundbreaking Partnership in RNA Therapeutics for Liver Diseases GSK Plc strengthens its position in the biotechnology landscape through a pivotal collaboration with Ochre Bio…
GSK Plc Faces Rising Short Interest Amid Market Dynamics GSK Plc, a prominent player in the pharmaceutical industry, is currently experiencing a significant rise in short interest, which has increased…
FDA Advances Drug Development with National Priority Voucher Program In a significant development for the pharmaceutical industry, the U.S. Food and Drug Administration (FDA) announces the awarding of…
### FDA Expands National Priority Voucher Program to Enhance Drug Development The U.S. Food and Drug Administration (FDA) recently announces the addition of six new companies awarded under the Commiss…
GSK's Strategic Positioning Ahead of Earnings Report Amid Market Uncertainty As GSK Plc prepares to release its earnings report this Thursday, the pharmaceutical giant finds itself navigating a landsc…